Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Revenue Performance and Segment Breakdown
BDX logo

BD Reports $5.25 Billion Revenue and Plans $2 Billion Share Repurchase Post-Spin-off

BDX10-QFiling Date: 2/9/2026
Becton, Dickinson and Company
Description

What this story covers

Becton Dickinson (BDX) reported 4.3% currency-neutral revenue growth in Q1 2026, driven by Pharmacy Automation and GLP-1 biologics. Despite China VoBP and regulatory headwinds, BD is executing a major segment reorganization and a $4 billion divestiture to Waters Corporation.

Story snapshot

CompanyBecton, Dickinson and Company
TickerBDX
VariantStandard detailed
Duration17:32
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000010795-26-000005
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in